Finotonlimab plus bevacizumab unlikely cost-effective vs. sorafenib for HCC in China
Finotonlimab plus bevacizumab showed increased survival benefits but was not cost-effective compared to sorafenib.
Asset / Drug
Drug and asset intelligence for finotonlimab with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.